1. Imatinib mesylate, a selective inhibitor of BCR-ABL, in chronic myeloid leukemia.
- Author
-
Carella AM
- Subjects
- Adenosine Triphosphate metabolism, Antineoplastic Agents pharmacology, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Benzamides, Binding Sites drug effects, Cross-Over Studies, Cytarabine administration & dosage, Disease-Free Survival, Drug Design, Drug Resistance, Neoplasm, Drugs, Investigational, Europe, Fusion Proteins, bcr-abl genetics, Fusion Proteins, bcr-abl physiology, Hematopoietic Stem Cell Transplantation, Humans, Imatinib Mesylate, Interferon-alpha administration & dosage, Leukemia, Myelogenous, Chronic, BCR-ABL Positive enzymology, Leukemia, Myelogenous, Chronic, BCR-ABL Positive genetics, Leukemia, Myelogenous, Chronic, BCR-ABL Positive surgery, Multicenter Studies as Topic, Neoplasm Proteins genetics, Neoplasm Proteins physiology, Piperazines administration & dosage, Piperazines pharmacology, Practice Guidelines as Topic, Protein Kinase Inhibitors pharmacology, Pyrimidines administration & dosage, Pyrimidines pharmacology, Randomized Controlled Trials as Topic, Transplantation, Homologous, Treatment Outcome, src Homology Domains drug effects, Antineoplastic Agents therapeutic use, Fusion Proteins, bcr-abl antagonists & inhibitors, Leukemia, Myelogenous, Chronic, BCR-ABL Positive drug therapy, Neoplasm Proteins antagonists & inhibitors, Piperazines therapeutic use, Protein Kinase Inhibitors therapeutic use, Pyrimidines therapeutic use
- Published
- 2007
- Full Text
- View/download PDF